FDA grants accelerated approval to groundbreaking rectal cancer immunotherapy
A groundbreaking immunotherapy treatment for rectal cancer, developed through pioneering research at Memorial Sloan Kettering Cancer Center (MSK) with critical early-stage funding from Swim Across America, has received accelerated approval from the U.S. Food and Drug Administration (FDA).
Read original article on The Medical News →Related news
-
Early uptake for oral semaglutide proves rapid relative to injectables
United Kingdom
-
Beyond the ACE score: A single number may miss the complexity of childhood trauma, study suggests
United Kingdom
-
ADHD medication unlikely to raise risk of self-harm, international study finds
United Kingdom
-
Adults with type 1 diabetes more likely to have depressive, anxiety symptoms
United Kingdom
-
Nurses are an important resource in Swedish bowel cancer screening
United Kingdom
-
Imaging study links several schizophrenia symptoms to a single brain signal
United Kingdom
-
Intermittent fasting plus exercise boosts fat loss and fitness in 12-week obesity trial
United Kingdom
-
Prevalence of binge eating 40.5% in U.S. high school students
United Kingdom